Evaluation of soluble CD279 (sCD279) and CD274 (sCD274) in Iraqi patients with Acute Myeloid Leukemia (AML) with Toxoplasmosis

Abstract

Abstract Toxoplasma gondii has been suggested as an important opportunistic pathogen in immunocompromised patients. Possible associations of parasite infection with cancer risk have recently attracted much attention. Published studies concerning the association between Toxoplasma gondii infection and leukemia risk have generated inconsistent results. In the present study, we aimed was to investigate the sero- prevalence of the anti-Toxoplasma gondii IgG antibodies in Iraqi patients with Acute Myeloid Leukemia (AML) with Toxoplasmosis and to clarify the role of sCD249 and sCD274 in Iraqi AML patients with toxoplasmosis. Enzyme Linked Immunosorbent Assay (ELISA) was used to detect anti- T. gondii IgG antibodies in the sera of 120 patients with AML and 50 apparently healthy controls. The results showed that 49(41%) samples of sera patients have been founded AML with toxoplasmosis, 71(59%) samples have AML, 20(40%) cases have control toxoplasmosis (those patients were had toxoplasmosis but showing no symptoms) and 30 (60%) cases samples were considered as a control group without any infections. Sera (sCD279 and sCD274) levels were determined by ELISA using a quantitative sandwich enzyme immunoassay technique. The results showed that levels of sCD279 and sCD274 levels were significantly higher in patients group than healthy subjects (P<0.01).